The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of licensing agreements from 2014 to 2019.

There has been a long standing willingness for parties to enter licensing deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

Licensing is a specific type of partnering deal whereby the parties to the deal agree to commercialize a compound, product or technology.

Specifically, licensing is the granting of permission to use intellectual property rights, such as trademarks, patents, or technology, under defined conditions

There are several forms of licensing deal. Traditional licensing arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subsequent sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful period of collaboration on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the licensing agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

Other forms of licensing such as sub-licensing and cross-licensing are also explored, with examples provided together with listing of recent deals in pharma, biotech and diagnostics.

The report provides a detailed understand and analysis of how and why companies enter licensing deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all licensing deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of licensing deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading licensing deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a review of the top 25 most active biopharma companies in licensing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a comprehensive review of licensing financials for deals announced since 2014, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.

Chapter 7 provides a comprehensive and detailed review of licensing deals signed and announced since 2014 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in licensing deal making since 2014.

In addition, a comprehensive appendix is provided organized by licensing company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing partnering in the research, development and commercialization of technologies and products.

Key benefits

Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 provides the reader with the following key benefits:

• In-depth understanding of licensing partnering deal trends since 2014
• Analysis of the structure of licensing agreements with numerous real life case studies
• Comprehensive listing of licensing deals since 2014, together with deal terms, value and press release
• Comprehensive access to actual licensing contracts entered into by the world’s life science companies
• Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
• Insight into the terms included in a licensing agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals           
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.        

Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 includes:

• Trends in licensing dealmaking in the biopharma industry since 2014
• Analysis of licensing deal structure
• Case studies of real-life licensing deals
• Comprehensive listing of licensing deals since 2014
• Access to licensing contract documents
• Key financial bnchmarks for headline, upfront, milestone and royalty rates
• The leading licensing deals by value since 2014
• Most active licensing dealmakers since 2014
• The leading licensing partnering resources

In Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?

• What is actually granted by the agreement to the partner company?

• What exclusivity is granted?

• What is the payment structure for the deal?

• How do milestone align with clinical stage development phases?

• How aresalesand payments audited?

• What is the deal term?

• How are the key terms of the agreement defined?

• How are IPRs handled and owned?

• Who is responsible for commercialization?

• Who is responsible for development, supply, and manufacture?

• How is confidentiality and publication managed?

• How are disputes to be resolved?

• Under what conditions can the deal be terminated?

• What happens when there is a change of ownership?

• What sublicensing and subcontracting provisions have been agreed?

• Which boilerplate clauses does the company insist upon?

• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

• Which jurisdiction does the company insist upon for agreement law?

Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2019 provides the reader with the following key benefits:

• In-depth understanding of licensing partnering deal trends since 2014
• Insight into the terms included in a licensing agreement, together with real world clause examples
•  Identify leading licensing deals by value since 2014
• Identify the most active licensing dealmakers since 2014
• Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
• Full listing of  licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
• Comprehensive access to licensing deals entered into by the world’s biopharma companies, together with contract documents if available
• Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in licensing deal making

2.1. Introduction

2.2. Definition of licensing deals

2.3. Success factors for licensing deals

2.4. When licensing can be useful

2.5. Attributes of licensing deals

2.6. Trends in licensing deals since 2014

2.6.1. Licensing deal making by year since 2014

2.6.2. Licensing deal making by phase of development since 2014

2.6.3. Licensing deal making by industry sector since 2014

2.6.4. Licensing deal making by therapy area since 2014

2.6.5. Licensing deal making by technology type since 2014

2.6.6. Licensing deal making by most active company since 2014

2.7. Option to license

2.8. Adding co-promotion to the mix

2.9. The future of licensing deals

Chapter 3 – Overview of licensing deal structure

3.1. Introduction

3.2. Pure versus multi-component licensing deals

3.3. Pure licensing agreement structure

3.3.1. Example licensing agreements

3.3.1.a. Case study 1: Ignyta – Nerviano Medical Sciences

3.3.1.b. Case study 2: Sanofi - Pozen

3.4. Licensing rights as part of a wider alliance agreement

3.4.1. Example licensing clauses

3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure

3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals

3.4.2. Example licensing option right clauses

3.4.2.a. Case study 5: Forest Laboratories - Trevena

3.4.2.b. Case study 6: Abbvie – Receptos

Chapter 4 – Leading licensing deals

4.1. Introduction

4.2. Top licensing deals by value

Chapter 5 – Top 25 most active licensing dealmakers

5.1. Introduction

5.2. Top 25 most active licensing dealmakers

Chapter 6 – Licensing deal term financials

6.1. Introduction

6.2. Licensing partnering headline values

6.3. Licensing deal upfront payments

6.4. Licensing deal milestone payments

6.5. Licensing royalty rates

Chapter 7 – Licensing contract directory since 2014

7.1. Introduction

7.2. Licensing deals with contracts since 2014

Appendices

Appendix 1 – Licensing dealmaking by companies A-Z

Appendix 2 – Licensing dealmaking by industry sector

Appendix 3 – Licensing dealmaking by stage of development

Appendix 4 – Licensing dealmaking by therapy area

Appendix 5 – Licensing dealmaking by technology type

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Definition of licensing

Figure 2: Situations where licensing can prove useful

Figure 3: Key attributes of a licensing deal

Figure 4: Trends in licensing deal announcements since 2014

Figure 5: Licensing deals signed at each phase of development since 2014

Figure 6: Licensing deals by industry sector since 2014

Figure 7: Licensing deals by therapy area since 2014

Figure 8: Licensing deals by technology type since 2014

Figure 9: Top 25 most active licensing dealmakers sinnce 2014

Figure 10: Licensing agreements – what should a contract include?

Figure 11: Components of the licensing deal structure

Figure 12: Top licensing deals by value since 2014

Figure 13: Most active licensing dealmakers since 2014

Figure 14: Licensing deals with a headline value

Figure 15: Licensing deals with an upfront value

Figure 16: Licensing deals with a milestone value

Figure 17: Licensing deals with a royalty rate value

Pricing options

• $2,995: single-user
• $4,495: multi-user
• $8,995: single site license
• $14,995: global site license

A full explanation of license type definitions can be found here.

Our guarantee

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.